Glycovax-002

Glycovax-002 is a glycoconjugate vaccine candidate developed by Glycovax Pharma to target severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19. The vaccine is designed as an immunostimulant and utilizes a semi-synthetic approach, combining a customizable linker, the CRM197 carrier protein, and a novel immunostimulating adjuvant. It is administered via intramuscular injection and aims to induce an immune response against SARS-CoV-2. Glycovax-002 has been evaluated in phase I clinical trials to assess its safety, reactogenicity, and immunogenicity in healthy adults aged 18–55 years[1][2][3][4][5].